Icon Wealth Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Icon Wealth Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-424	Closed	-$15K	–	688
2019 Q1	$15K	Buy	+424	New	+$15.8K	0.01%	614
2018 Q3	–	Sell	-353	Closed	-$21K	–	667
2018 Q2	$21K	Buy	+353	New	+$18.3K	0.01%	583
2018 Q1	–	Sell	-329	Closed	-$13K	–	663
2017 Q4	$13K	Buy	+329	New	+$13K	0.01%	686

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Icon Wealth Partners's SUPN Position: Q2 2019 in Review

Icon Wealth Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 424 shares — an estimated $15K sold.

Icon Wealth Partners first reported a position in SUPN in Q4 2017 and held it in 3 quarters. The position peaked at $21K in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Icon Wealth Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Icon Wealth Partners sold 424 Supernus Pharmaceuticals shares in Q2 2019, an estimated $15K.
Icon Wealth Partners first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Icon Wealth Partners's Supernus Pharmaceuticals position peaked at $21K in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Icon Wealth Partners's 13F filing for Q2 2019, filed 13 Aug 2019.